Cyclerion Therapeutics, Inc. (CYCN)
- Previous Close
2.9500 - Open
2.8800 - Bid --
- Ask --
- Day's Range
2.8800 - 2.8801 - 52 Week Range
1.7500 - 6.7500 - Volume
601 - Avg. Volume
2,526 - Market Cap (intraday)
7.805M - Beta (5Y Monthly) 1.83
- PE Ratio (TTM)
-- - EPS (TTM)
-5.3900 - Earnings Date Jul 26, 2024 - Jul 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
www.cyclerion.comRecent News: CYCN
Performance Overview: CYCN
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYCN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYCN
Valuation Measures
Market Cap
8.54M
Enterprise Value
965.80k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.76
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.34%
Return on Equity (ttm)
-115.85%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.59M
Diluted EPS (ttm)
-5.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
7.57M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.52M
Research Analysis: CYCN
Company Insights: CYCN
CYCN does not have Company Insights